Ecopipam reduces relapse risk in pediatric Tourette syndrome

1. Ecopipam is a first-in-class investigational selective dopamine D1 receptor antagonist under priority review for pediatric Tourette syndrome, offering a pharmacologic mechanism distinct from treatments centered on dopamine D2 receptor blockade.

2. In a phase 3 randomized withdrawal trial, pediatric responders who continued ecopipam had a 53% lower risk of relapse than those transitioned to placebo, without clinically meaningful changes in weight, metabolic measures, or assessments of drug-induced movement disorders.

Tourette syndrome can substantially impair social, educational, and psychological functioning, yet pharmacologic treatment often requires families to balance tic reduction against adverse effects that become particularly consequential during long-term treatment in children. On August 19, 2026, the U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) for ecopipam and granted priority review for pediatric Tourette syndrome. Ecopipam selectively antagonizes the dopamine D1 receptor, distinguishing it mechanistically from antipsychotic therapies whose therapeutic and adverse effects are largely mediated through dopamine D2 receptor blockade. The development program includes the phase 2b D1AMOND trial, in which pediatric patients receiving ecopipam demonstrated statistically significant improvement in tic severity compared with placebo after 12 weeks. The subsequent phase 3 randomized withdrawal study enrolled 216 participants into an initial open-label treatment period and then randomized responders to either continue ecopipam or transition to placebo. Among pediatric participants, continued treatment produced a 53% lower relapse risk than placebo during the 12-week randomized period. A randomized withdrawal design is particularly useful for evaluating maintenance of response, although it answers a different question from a conventional parallel-group trial comparing treatment initiation with placebo across an unselected population.

The safety findings are clinically important because investigators did not identify meaningful changes in weight, metabolic measures, psychiatric scales, or assessments of drug-induced movement disorders during the study. Somnolence, anxiety, headache, insomnia, fatigue, and tics were among the more frequently reported adverse events, meaning a different dopamine target does not eliminate the need for careful tolerability assessment. The D1-selective mechanism is therefore promising because it may provide tic control without some liabilities associated with broader dopamine antagonism, but superiority in long-term safety should not be assumed before larger and longer clinical experience is available. Priority review shortens the regulatory review timeline for therapies that may offer significant improvements in treatment, but it does not imply that the FDA has already concluded that ecopipam is safe or effective enough for approval. The agency has assigned a target action date in late first-quarter 2027, leaving ecopipam investigational until that review is completed. If approved, the most clinically meaningful role may be among children whose functionally impairing tics warrant pharmacotherapy but for whom adverse effects or inadequate response limit existing options. Ecopipam therefore represents an unusually substantive development in Tourette pharmacotherapy because both its receptor target and randomized maintenance data differ from much of the existing treatment landscape, while the upcoming FDA decision will determine whether those findings are sufficient to bring the first selective dopamine D1 antagonist into clinical practice.

Image: PD

©2026 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.